TeraWulf
WULF
Bitdeer Technologies
BTDR
Riot Platforms
RIOT
Bitfarms
BITF
CleanSpark
CLSK
US Stock MarketDetailed Quotes
PALI Palisade Bio
- 0.8290
- +0.0050+0.61%
Close Feb 28 16:00 ET
- 0.8210
- -0.0080-0.96%
Post 20:01 ET
2.29MMarket Cap-0.06P/E (TTM)
0.8500High0.8000Low43.99KVolume0.8256Open0.8240Pre Close36.39KTurnover1.79%Turnover RatioLossP/E (Static)2.77MShares9.650052wk High0.35P/B2.04MFloat Cap0.800052wk Low--Dividend TTM2.46MShs Float594000.0000Historical High--Div YieldTTM6.07%Amplitude0.8000Historical Low0.8270Avg Price1Lot Size
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Palisade Bio Stock Forum
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)
Thursday, 20th February at 8:45 am
Company through its co-development partner, Giiant Pharma, Inc. ("Giiant"), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax Credit Program for PALI-2108
Ongoing progress of Palisade Bio's Phase 1a/b UC st...
2 MINUTES AGO, 8:45 AM EST
VIA GLOBENEWSWIRE
Data presented at the 2025 Crohn's and Colitis Congress
PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure
Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
Monday, 10th February at 8:45 am
Data presented at the 2025 Crohn's and Colitis Congress
PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure
Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts
Carlsbad, CA, Fe...
Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress
Wednesday, 29th January at 8:45 am
Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepte...
No comment yet